乳腺癌肿瘤微环境中间质细胞介导的化疗耐药性研究进展

doi:10.11904/j.issn.1002-3070.2020.04.017

Abstract

Abstract: Breast cancer is a heterogeneous systemic disease.Its microenvironment is mainly composed of tumor cells and a variety of non-tumor cells.Among them,mesenchymal stem cells(MSCs)play an important role in tumorigenesis and development.MSCs can interact with tumor cells and their microenvironment directly through gap junctions,membrane receptors and microtubules,or indirectly through soluble molecules.Tumor-associated fibroblasts(CAFs)are derived from adjacent cancer fibroblasts or MSCs,and play an important role in tumor drug resistance.In breast cancer,tumor stem cells and their microenvironment are in a dynamic equilibrium state,and their phenotype is closely regulated by cytokines.Interstitial cells have an important effect on their biological characteristics through their interaction with breast cancer cells.In addition,interstitial cells can change the sensitivity of tumor cells to chemotherapeutic drugs,which in turn make them resistant.Therefore,addressing tumor stromal cell-mediated resistance to chemotherapy is the key to successful treatment of advanced breast cancer.This article mainly describes the research progress of stromal cells in the microenvironment mediated chemotherapy resistance of breast cancer.

Key words: Breast cancer, Tumor mesenchymal cells, Chemotherpy resistance

CLC Number:

R737.9

CHEN Du, QIAN Cheng. Research progress of mesenchymal cell-mediated chemotherapy resistance in tumor microenvironment of breast cancer[J]. Journal of Practical Oncology, 2020, 34(4): 382-386.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2020.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2020/V34/I4/382

References

1 Kadakia KC,Kidwell KM,Barton DL,et al.Factors influencing the use of extended adjuvant endocrine therapy[J].Breast Cancer Res Treat,2019,175(1):181-189.
2 Guo F,Kuo YF,Shih Y,et al.Trends in breast cancer mortality by stage at diagnosis among young women in the United States[J].Cancer,2018,124(17):3500-3509.
3 Plava J,Cihova M,Burikova M,et al.Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer[J].Mol Cancer,2019,18(1):67.
4 Halama N,Zoernig I,Berthel A,et al.Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients[J].Cancer Cell,2016,29(4):587-601.
5 Autenshlyus AI,Davletova KI,Studenikina AA,et al.Cytokine production by blood immune cells,tumor and its microenvironment,characteristic of extracellular matrix in patients with invasive ductal carcinoma of no special type[J].Biomed Khim,2019,65(5):424-431.
6 Kucerova L,Durinikova E,Toro L,et al.Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells[J].Cancer Lett,2017,408:1-9.
7 Sridharan S,Howard CM,Tilley A,et al.Novel and alternative targets against breast cancer stemness to combat chemoresistance[J].Front Oncol,2019,9:1003.
8 Grisendi G,Spano C,Rossignoli F,et al.Tumor stroma manipulation by MSC[J].Curr Drug Targets,2016,17(10):1111-1126.
9 Ireland LV,Mielgo A.Macrophages and fibroblasts,key players in cancer chemoresistance[J].Front Cell Dev Biol,2018,6:131.
10 Borriello L,Nakata R,Sheard MA,et al.Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells[J].Cancer Res,2017,77(18):5142-5157.
11 Su S,Chen J,Yao H,et al.CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness[J].Cell,2018,172(4):841-856.
12 Melzer C,Yang Y,Hass R.Interaction of MSC with tumor cells[J].Cell Commun Signal,2016,14(1):20.
13 Zhou X,Li T,Chen Y,et al.Mesenchymal stem cell derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway[J].Int J Oncol,2019,54(5):1843-1852.
14 Kucerova L,Durinikova E,Toro L,et al.Targeted antitumor therapy mediated by prodrug-activating mesenchymal stromal cells[J].Cancer Lett,2017,408:1-9.
15 Hill BS,Pelagalli A,Passaro N,et al.Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype[J].Oncotarget,2017,8(42):73296-73311.
16 Rhee KJ,Lee JI,Eom YW.Mesenchymal stem cell-mediated effects of tumor support or suppression[J].Int J Mol Sci,2015,16(12):30015-30033.
17 Han HR,Park SA,Ahn S,et al.Evaluation of combination treatment effect with trail-secreting mesenchymal stem cells and compound c against glioblastoma[J].Anticancer Res,2019,39(12):6635-6643.
18 Maffey A,Storini C,Diceglie C,et al.Mesenchymal stem cells from tumor microenvironment favour breast cancer stem cell proliferation,cancerogenic and metastatic potential,via ionotropic purinergic signalling[J].Sci Rep,2017,7(1):13162.
19 Jin OH,Hee WL,Kyoung WS,et al.Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma[J].PLoS One,2013,8(9):e74897.
20 Chan TS,Shaked Y,Tsai KK.Targeting the interplay between cancer fibroblasts,mesenchymal stem cells,and cancer stem cells in desmoplastic cancers[J].Front Oncol,2019,9:688.
21 Smit L,Berns K,Spence K,et al.An integrated genomic approach identifies that the PI3K/Akt/FOXO pathway is involved in breast cancer tumor initiation[J].Oncotarget,2016,7(3):2596-2610.
22 Woosley AN,Dalton AC,Hussey GS,et al.TGFβ promotes breast cancer stem cell self-renewal through an ILEI/LIFR signaling axis[J].Oncogene,2019,38(20):3794-3811.
23 Miller-KJ,Guo X,Qian W,et al.Dual-targeting wnt and upa receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer[J].Biomaterials,2018,152:47-62.
24 Costa A,Kieffer Y,Scholer DA,et al.Fibroblast heterogeneity and immunosuppressive environment in human breast cancer[J].Cancer Cell,2018,33(3):463-479.
25 Morgan MM,Livingston MK,Warrick JW,et al.Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model[J].Sci Rep,2018,8(1):7139.
26 Wilson TR,Fridlyand J,Yan Y,et al.Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors[J].Elife,2014,3(7408):505-509.
27 Kalluri R.The biology and function of fibroblasts in cancer[J].Nat Rev Cancer,2016,16(9):582-598.
28 Unger C,Kramer N,Unterleuthner D,et al.Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms[J].Oncogene,2017,36(38):5341-5355.
29 Chan TS,Hsu CC,Pai VC,et al.Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells[J].J Exp Med,2016,213(13):2967-2988.
30 Wilcken N,Zdenkowski N,White M,et al.Systemic treatment of HER2-positive metastatic breast cancer:A systematic review[J].Asia Pac J Clin Oncol,2014,10:1-14.
31 Zhong H,Davis A,Ouzounova M,et al.A novel il6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors[J].Cancer Res,2016,76(2):480-490.
32 Liu S,Ginestier C,Ou SJ,et al.Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks[J].Cancer Res,2011,71(2):614-624.
33 Ono M,Kosaka N,Tominaga N,et al.Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells[J].Sci Signal,2014,7(332):63.
34 Cai Y,Xi Y,Cao Z,et al.Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells[J].Cancer Lett,2016,381(1):104-112.
35 Jiménez G,Hackenberg M,Catalina P,et al.Mesenchymal stem cell's secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile[J].Cancer Lett,2018,429:78-88.
36 Rudnick JA,Arendt LM,Klebba I,et al.Functional heterogeneity of breast fibroblasts is defined by a prostaglandin secretory phenotype that promotes expansion of cancer-stem like cells[J].PLoS One,2011,6(9):e24605.
37 Lim B,Woodward WA,Wang X,et al.Inflammatory breast cancer biology:the tumour microenvironment is key[J].Nat Rev Cancer,2018,18(8):485-499.
38 Valenti G,Quinn HM,Heynen G,et al.Cancer stem cells regulate cancer-associated fibroblasts via activation of hedgehog signaling in mammary gland tumors[J].Cancer Res,2017,77(8):2134-2147.
39 Ireland L,Santos A,Campbell F,et al.Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer[J].Oncogene,2018,37(15):2022-2036.
40 Schott AF,Goldstein LJ,Cristofanilli M,et al.Phase ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with her-2-negative metastatic breast cancer[J].Clin Cancer Res,2017,23(18):5358-5365.
41 Steele CW,Karim SA,Leach J,et al.CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma[J].Cancer Cell,2016,29(6):832-845.

[1]	ZHAO Rencheng, LIN Zitang, YU Weijun, LEI Lin, LIU Zheng, XU Ying, GUO Yanfang, PENG Ji. Analysis of the prevalence of five cancer risks among permanent residents aged 40~74 years old in Baoan District,Shenzhen,2017—2019 [J]. Journal of Practical Oncology, 2020, 34(4): 315-320.
[2]	TONG Xiao, XING Jiani, WANG Lihong. Long-chain noncoding RNA HCP5 promotes triple-negative breast cancer by regulating apoptotic pathway [J]. Journal of Practical Oncology, 2020, 34(4): 321-327.
[3]	LIU Siqi, BIAN Nana, SU Yajuan. Research on the value of ultrasound BI-RADS combined with serum CA15-3 and CEA in the diagnosis of breast tumors [J]. Journal of Practical Oncology, 2020, 34(4): 347-351.
[4]	ZHANG Rui, LI Zhigao. Clinical research progress of mucinous breast cancer [J]. Journal of Practical Oncology, 2020, 34(4): 377-381.
[5]	XIE Xianxin,WEI Jun,QIU Jiaxin,WANG Cong,JIANG Daqing. Analysis of histopathological information and prognosis of residual tumor in neoadjuvant chemotherapy for breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 225-231.
[6]	LI Hui,PANG Da. Clinicopathological characteristics and adjuvant treatment of triple positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(3): 262-265.
[7]	ZHAO Yunxia, NIU Bo. Effect of lncRNA NBAT1 on proliferation of breast cancer cells by regulating the molecular axis of miR-3664-5p/Caspase 9 [J]. Journal of Practical Oncology, 2020, 34(1): 24-29.
[8]	LI Guozheng, PANG Da. Progression in the treatment of HER2-positive breast cancer [J]. Journal of Practical Oncology, 2020, 34(1): 74-78.
[9]	CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy [J]. Journal of Practical Oncology, 2019, 33(6): 566-569.
[10]	SHEN Yizhe, GUO Baoliang. Progress in local treatment of newly diagnosed stage IV breast cancer [J]. Journal of Practical Oncology, 2019, 33(6): 575-578.
[11]	SHI Manru, E Mingyan. Effect of delayed radiotherapy on the prognosis of patients with different molecular subtypes of breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 431-435.
[12]	LI Lei, ZHANG Qingyuan. Clinical progress of anti-tumor vascular therapy for breast cancer [J]. Journal of Practical Oncology, 2019, 33(5): 461-465.
[13]	WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells [J]. Journal of Practical Oncology, 2019, 33(5): 466-470.
[14]	LIU Eryu, YANG Hao, LIANG Guohua, ZHAO Yanfang, ZHAO Wenhui. Action for CDK4/6 inhibitors combined with mTOR inhibitors in breast cancer and its mechanism [J]. Journal of Practical Oncology, 2019, 33(5): 476-480.
[15]	AN Weiwei, TANG Yali, ZHAO Lianhua, YANG Yue, WANG Xinling. Polyphenylene-polysaccharide complex from pinus koraiensis extract induces apoptosis in human breast cancer MCF-7 cells [J]. Journal of Practical Oncology, 2019, 33(4): 289-293.

Research progress of mesenchymal cell-mediated chemotherapy resistance in tumor microenvironment of breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments